Ga naar hoofdinhoud

Gebruik de knoppen om de artikels, publicaties en presentaties van deze auteur te raadplegen.

Efficacy of ruxolitinib in B-lymphoblastic leukaemia with PCM1-JAK2 fusion gene.

Br J Haematol. 2021 Feb;192(4):e112-e115. doi: 10.1111/bjh.17340. Epub 2021 Jan 27

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.

Leukemia. 2021 Jul;35(7):2119-2124. doi: 10.1038/s41375-021-01125-4. Epub 2021 Jan 22. PMID: 33483617 Free PMC article. Clinical Trial. No abstract available.

Efficacy of ruxolitinib in B-lymphoblastic leukaemia with the PCM1-JAK2 fusion gene.

Br J Haematol. 2021 Feb;192(4):e112-e115. doi: 10.1111/bjh.17340. Epub 2021 Jan 27. PMID: 33502001 No abstract available.

Primary immune thrombocytopenia in adults: Belgian recommendations for diagnosis and treatment anno 2021 made by the Belgian Hematology Society.

Acta Clin Belg. 2021 Feb 26:1-14. doi: 10.1080/17843286.2021.1876310. Online ahead of print. PMID: 33635747

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.

N Engl J Med. 2020 Dec 24;383(26):2526-2537. doi: 10.1056/NEJMoa2004444. PMID: 33369355 Clinical Trial.

Effectiveness and Safety of Romiplostim Among Patients with Newly Diagnosed, Persistent and Chronic Immune Thrombocytopenia in European Clinical Practice.

Adv Ther. 2021 May;38(5):2673-2688. doi: 10.1007/s12325-021-01727-5. Epub 2021 Apr 18. PMID: 33866516 Free PMC article.

Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.

Ann Hematol. 2021 Jul;100(7):1723-1732. doi: 10.1007/s00277-021-04507-x. Epub 2021 May 4. PMID: 33942128 Free PMC article.

A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease.

Bone Marrow Transplant. 2021 Oct;56(10):2477-2488. doi: 10.1038/s41409-021-01356-0. Epub 2021 Jun 9. PMID: 34108672 Free PMC article. Clinical Trial.

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.

J Hematol Oncol. 2021 Aug 28;14(1):133. doi: 10.1186/s13045-021-01142-x. PMID: 34454540 Free PMC article. Clinical Trial.

Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial.

Haematologica. 2021 Sep 23. doi: 10.3324/haematol.2021.279174. Online ahead of print. PMID: 34551506 Free article.

Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective study from the Belgian Hematology Society (BHS).

Bone Marrow Transplant. 2021 Oct 5. doi: 10.1038/s41409-021-01464-x. Online ahead of print. PMID: 34611291 No abstract available.

Acute thyrotoxicosis after SCT.

Bone Marrow Transplant. 2009 Apr;43(8):663-4. Epub 2008 Nov 17. No abstract available. PMID: 19011663 [PubMed - indexed for MEDLINE] PMID: 17986280

Targeted next generation DNA sequencing for the detection of clonal haematopoiesis in idiopathic cytopaenia of undetermined significance (ICUS).

Belgian Journal of Hematology 2019;10:231-40

Targeted next generation DNA sequencing for the detection of clonal haematopoiesis in idiopathic cytopaenia of undetermined significance (ICUS).

Belgian Journal of Hematology 2019;10:231-40

Targeted next generation DNA sequencing for the detection of clonal haematopoiesis in idiopathic cytopaenia of undetermined significance (ICUS).

BELG J HAEMATOL 2019;10(6):231-40

Mediastinal Myeloid Sarcoma with TP53 Mutation Preceding Acute Myeloid Leukemia with a PICALM-MLLT10 Fusion.

Acta Haematol 2018;140:97–104

“A disseminated Mycoplasma hominis infection in a patient with an underlying defect in humoral immunity”.

Infection. 44(3):379-81.

Clinical challenges and images in GI. Fasciola hepatica infection and Von Hippel-Lindau disease type 1 with pancreatic and renal involvement.

Gastroenterology 2007;132:15-6, 467-8.

Clinical challenges and images in GI. Fasciola hepatica infection and Von Hippel-Lindau disease type 1 with pancreatic and renal involvement.

Gastroenterology 2007;132:15-6, 467-8.
Geen resultaten gevonden
Back To Top